JO2990B1 - مركبات بروبان دائري - Google Patents
مركبات بروبان دائريInfo
- Publication number
- JO2990B1 JO2990B1 JOP/2011/0289A JOP20110289A JO2990B1 JO 2990 B1 JO2990 B1 JO 2990B1 JO P20110289 A JOP20110289 A JO P20110289A JO 2990 B1 JO2990 B1 JO 2990B1
- Authority
- JO
- Jordan
- Prior art keywords
- hydrogen atom
- independently represent
- atom
- cyclopropane compound
- alkyl group
- Prior art date
Links
- -1 Cyclopropane compound Chemical class 0.000 title abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 108050000742 Orexin Receptor Proteins 0.000 abstract 2
- 102000008834 Orexin receptor Human genes 0.000 abstract 2
- 230000008485 antagonism Effects 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract 1
- 206010022437 insomnia Diseases 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 208000020685 sleep-wake disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
يتمثل المركب cyclopropane في الصيغة التالية (A) أو ملح (salt) مقبول دوائيا منه حيث يمكن الانتفاع منه في معالجة اضطراب النوم الذي يفيد فيه معارضة مستقبل orexin، مثل الأرق: Q يمثل -CH- أو ذرة nitrogen، R1a وR1b كلاهما على حدة يمثل مجموعة C1-6 alkyl، إلخ، R1c يمثل ذرة hydrogen، إلخ، R2a، R2b، R2c وR2d كل منهم على حدة يمثل ذرة hydrogen، ذرة halogen، مجموعة C1-6 alkyl، إلخ، R3a، R3b وR3c كل منهم على حدة يمثل ذرة hydrogen، ذرة halogen، إلخ، R3d يمثل ذرة hydrogen، إلخ.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38534210P | 2010-09-22 | 2010-09-22 | |
| JP2010211629 | 2010-09-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JO2990B1 true JO2990B1 (ar) | 2016-09-05 |
Family
ID=45873858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2011/0289A JO2990B1 (ar) | 2010-09-22 | 2011-09-20 | مركبات بروبان دائري |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US8268848B2 (ar) |
| EP (1) | EP2626350B1 (ar) |
| JP (1) | JP4944286B1 (ar) |
| KR (1) | KR101458007B1 (ar) |
| CN (1) | CN103153963B (ar) |
| AR (1) | AR083060A1 (ar) |
| AU (1) | AU2011304285B2 (ar) |
| BR (1) | BR112013006594B1 (ar) |
| CA (1) | CA2811895C (ar) |
| CL (1) | CL2013000784A1 (ar) |
| DK (1) | DK2626350T3 (ar) |
| ES (1) | ES2540851T3 (ar) |
| IL (1) | IL225437A (ar) |
| JO (1) | JO2990B1 (ar) |
| MA (1) | MA34609B1 (ar) |
| MX (1) | MX2013003218A (ar) |
| MY (1) | MY160969A (ar) |
| NZ (1) | NZ609313A (ar) |
| PE (1) | PE20131162A1 (ar) |
| PL (1) | PL2626350T3 (ar) |
| PT (1) | PT2626350E (ar) |
| RS (1) | RS54101B1 (ar) |
| RU (1) | RU2571414C2 (ar) |
| SG (1) | SG188585A1 (ar) |
| SI (1) | SI2626350T1 (ar) |
| TW (1) | TWI516484B (ar) |
| UA (1) | UA108510C2 (ar) |
| WO (1) | WO2012039371A1 (ar) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104114524B (zh) | 2012-02-17 | 2016-08-17 | 卫材R&D管理有限公司 | 用于食欲肽-2受体拮抗剂的合成的方法和化合物 |
| EP2922823B1 (en) | 2012-11-20 | 2018-10-31 | Merck Sharp & Dohme Corp. | Pyrimidine pde10 inhibitors |
| HUE043849T2 (hu) | 2014-08-06 | 2019-09-30 | Eisai R&D Man Co Ltd | Eljárás pirimidin-1-ol vegyület és annak intermediere elõállítására |
| CN107810006B (zh) * | 2014-10-23 | 2021-03-30 | 卫材R&D管理有限公司 | 用于治疗失眠的组合物 |
| CN108368122A (zh) | 2015-10-29 | 2018-08-03 | 国立大学法人筑波大学 | 吗啡喃衍生物及其药物用途 |
| EP4056180A1 (en) | 2016-05-12 | 2022-09-14 | Eisai R&D Management Co., Ltd. | Methods of treating circadian rhythm sleep disorders |
| CN115710250A (zh) * | 2017-08-01 | 2023-02-24 | 博健制药有限责任公司 | 一种食欲素受体拮抗剂的晶型及其制备方法和用途 |
| US20220194925A1 (en) | 2019-05-15 | 2022-06-23 | Eisai R&D Management Co., Ltd. | Method and compound useful in preparation of orexin-2 receptor antagonist, and lemborexant having few impurities |
| BR112021026291A2 (pt) * | 2019-06-26 | 2022-03-03 | Eisai R&D Man Co Ltd | Lemborexant para tratar problemas de sono |
| EP4073058A1 (en) | 2019-12-11 | 2022-10-19 | Teva Czech Industries s.r.o. | Solid state form of lemborexant |
| CN115003305A (zh) | 2019-12-20 | 2022-09-02 | 卫材R&D管理有限公司 | 使用莱博雷生治疗失眠 |
| EP4059504A4 (en) | 2020-01-16 | 2023-12-27 | Eisai R&D Management Co., Ltd. | LEMBOREXANT MEDICINAL COMPOSITION AND MEDICAL COMPOSITION CONTAINING SAME |
| WO2021205648A1 (ja) * | 2020-04-10 | 2021-10-14 | 国立大学法人東海国立大学機構 | 精神障害患者の客観的睡眠評価方法 |
| EP4376954A1 (en) | 2021-07-26 | 2024-06-05 | Eisai R&D Management Co., Ltd. | Lemborexant for use in methods of treating irregular sleep-wake rhythm disorder and circadian rhythm sleep disorders associated with neurodegenerative diseases |
| WO2023178702A1 (zh) * | 2022-03-25 | 2023-09-28 | 浙江华海药业股份有限公司 | 莱博雷生及其中间体化合物的制备方法 |
| WO2023178693A1 (zh) * | 2022-03-25 | 2023-09-28 | 浙江华海药业股份有限公司 | 一种莱博雷生及其中间体的制备方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06328057A (ja) | 1993-05-26 | 1994-11-29 | Sanyo Electric Co Ltd | 厨芥処理装置 |
| WO1996034877A1 (en) | 1995-05-05 | 1996-11-07 | Human Genome Sciences, Inc. | Human neuropeptide receptor |
| CN1152679C (zh) * | 1996-12-10 | 2004-06-09 | 布里斯托尔-迈尔斯斯奎布公司 | 苯并二氧杂环戊烯、苯并呋喃、二氢苯并呋喃和苯并二噁烷类化合物褪黑激素能药剂 |
| US6309854B1 (en) | 1996-12-17 | 2001-10-30 | Smithkline Beecham Corporation | Polynucleotides encoding ligands of the neuropeptide receptor HFGAN72 |
| US6001963A (en) | 1996-12-17 | 1999-12-14 | Smithkline Beecham Corporation | Ligands of the neuropeptide receptor HFGAN72 |
| US5935814A (en) | 1997-04-30 | 1999-08-10 | Smithkline Beecham Corporation | Polynucleotides encoding HFGAN72Y receptor |
| US6020157A (en) | 1997-04-30 | 2000-02-01 | Smithkline Beecham Corporation | Polynucleotides encoding HFGAN72X receptor |
| US6166193A (en) | 1997-07-25 | 2000-12-26 | Board Of Regents, University Of Texas System | Polynucleotides encoding MY1 receptor |
| NZ550216A (en) | 2004-03-01 | 2009-08-28 | Actelion Pharmaceuticals Ltd | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives |
| JP2008513434A (ja) * | 2004-09-23 | 2008-05-01 | ファイザー・プロダクツ・インク | トロンボポイエチン受容体アゴニスト |
| CN101155792A (zh) * | 2005-04-12 | 2008-04-02 | 默克公司 | 氨基丙氧基苯基增食欲素受体拮抗剂 |
| US20080262046A1 (en) * | 2005-04-12 | 2008-10-23 | Coleman Paul J | Amidopropoxyphenyl Orexin Receptor Antagonists |
| JP2006328057A (ja) * | 2005-04-25 | 2006-12-07 | Eisai R & D Management Co Ltd | 抗不安薬及びそのスクリーニング方法 |
| US20090082394A1 (en) | 2006-03-15 | 2009-03-26 | Actelion Pharmaceuticals, Ltd. | Tetrahydroisoquinoline Derivatives to Enhance Memory Function |
| WO2007129188A1 (en) | 2006-05-10 | 2007-11-15 | Pfizer Japan Inc. | Cyclopropanecarboxamide compound |
| JP2009184924A (ja) | 2006-05-31 | 2009-08-20 | Eisai R & D Management Co Ltd | 生物学的試薬用化合物 |
| PE20081368A1 (es) | 2006-09-11 | 2008-11-19 | Glaxo Group Ltd | Derivados de azabiciclo[4.1.0]heptano como inhibidores de la recaptacion de serotonina, dopamina y norepinefrina |
| ES2350460T3 (es) | 2006-09-29 | 2011-01-24 | Actelion Pharmaceuticals Ltd. | Derivados de 3-aza-biciclo[3.1.0]hexano. |
| PE20081229A1 (es) | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
| CL2007003827A1 (es) * | 2006-12-28 | 2008-09-26 | Actelion Pharmaceuticals Ltd | Compuestos derivados de n-(2-aza-biciclo(3.1.0)hex-3-ilmetil)amida; y su uso para prevenir o tratar la depresion, neurosis, esquizofrenia, ansiedad, adicciones, epilepsia, dolor, enfermedades cardiacas, entre otras. |
| AU2008303975B2 (en) | 2007-09-21 | 2013-05-16 | Sanofi | (Cyclopropyl-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament |
| PE20091010A1 (es) | 2007-10-10 | 2009-08-08 | Actelion Pharmaceuticals Ltd | Derivados de tetrahidroquinolina |
| UY32277A (es) * | 2008-12-02 | 2010-05-31 | Glaxo Group Ltd | Derivados de n-{[1r,4s,6r)-3-(2-piridinilcarbonil)-3-azabiciclo[4.1.0-il}metil}-2heteroarilamina y uso de los mismos |
| US20120165339A1 (en) * | 2010-12-22 | 2012-06-28 | Eisai R&D Management Co., Ltd. | Cyclopropane derivatives |
-
2011
- 2011-09-20 MX MX2013003218A patent/MX2013003218A/es active IP Right Grant
- 2011-09-20 WO PCT/JP2011/071325 patent/WO2012039371A1/ja active Application Filing
- 2011-09-20 MA MA35823A patent/MA34609B1/fr unknown
- 2011-09-20 CA CA2811895A patent/CA2811895C/en active Active
- 2011-09-20 TW TW100133754A patent/TWI516484B/zh active
- 2011-09-20 UA UAA201304939A patent/UA108510C2/ru unknown
- 2011-09-20 PT PT118268168T patent/PT2626350E/pt unknown
- 2011-09-20 MY MYPI2013000954A patent/MY160969A/en unknown
- 2011-09-20 US US13/237,205 patent/US8268848B2/en active Active
- 2011-09-20 EP EP11826816.8A patent/EP2626350B1/en active Active
- 2011-09-20 AR ARP110103428A patent/AR083060A1/es active IP Right Grant
- 2011-09-20 SG SG2013019880A patent/SG188585A1/en unknown
- 2011-09-20 KR KR1020137009631A patent/KR101458007B1/ko active IP Right Grant
- 2011-09-20 SI SI201130507T patent/SI2626350T1/sl unknown
- 2011-09-20 ES ES11826816.8T patent/ES2540851T3/es active Active
- 2011-09-20 PL PL11826816T patent/PL2626350T3/pl unknown
- 2011-09-20 JP JP2012500752A patent/JP4944286B1/ja active Active
- 2011-09-20 CN CN201180045556.7A patent/CN103153963B/zh active Active
- 2011-09-20 BR BR112013006594-0A patent/BR112013006594B1/pt active IP Right Grant
- 2011-09-20 PE PE2013000532A patent/PE20131162A1/es active IP Right Grant
- 2011-09-20 NZ NZ609313A patent/NZ609313A/en unknown
- 2011-09-20 DK DK11826816.8T patent/DK2626350T3/en active
- 2011-09-20 JO JOP/2011/0289A patent/JO2990B1/ar active
- 2011-09-20 AU AU2011304285A patent/AU2011304285B2/en active Active
- 2011-09-20 RS RS20150418A patent/RS54101B1/en unknown
- 2011-09-20 RU RU2013117464/04A patent/RU2571414C2/ru active
-
2013
- 2013-03-21 IL IL225437A patent/IL225437A/en active IP Right Grant
- 2013-03-21 CL CL2013000784A patent/CL2013000784A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JO2990B1 (ar) | مركبات بروبان دائري | |
| PH12016501535A1 (en) | Uracil derivatives as axl and c-met kinase inhibitors | |
| PH12015502232A1 (en) | Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists | |
| MX2011013016A (es) | Derivados de aminopirrolidinona y usos de los mismos. | |
| MY185217A (en) | Analogs of glucagon exhibiting gip receptor activity | |
| MX2013006304A (es) | Analogos de glucagon que exhiben actividad del receptor gip. | |
| GEP201706616B (en) | Hydrazide containing nuclear transport modulators and usage thereof | |
| JO3116B1 (ar) | مشتق بيرازولوكينولين كمثبطات ل pde9 | |
| MX2015011180A (es) | Derivados de aril sulfamida y sulfamato como moduladores del receptor huerfano relacionado con el receptor del retinoide (porc). | |
| PH12016500480A1 (en) | Antibacterial 2h-indazole derivatives | |
| MX337392B (es) | Sujetador de seguridad. | |
| WO2010102154A3 (en) | Biaryl oxyacetic acid compounds | |
| DK2569178T3 (da) | Indretning til justering af positionen og fastgørelse af et låseorgan på en bærer med udligning af spillerum | |
| IN2014CN02036A (ar) | ||
| MY171954A (en) | New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | |
| GB201020397D0 (en) | Compounds | |
| JO2854B1 (ar) | طريقة جديدة لتركيب الأنفابرادين وأملاحه المضافة مع حمض يكون مقبولا صيدلانيا. | |
| TN2013000119A1 (en) | Cyclopropane compounds | |
| MX2011010358A (es) | Derivados de 2-hidroxietil-1h-quinolin-2-ona y sus analogos azaisostericos con actividad antibacteriana. | |
| CY1116553T1 (el) | Ενωση κυκλοπροπανιου | |
| SA113340412B1 (ar) | عملية جديدة لتصنيع إيڤابرادين وأملاح إضافة منه مع حمض مقبول صيدلانياً | |
| EP2621891A4 (en) | POLYMORPHES OF 4- [2-DIMETHYLAMINO-1- (1-HYDROXYCYCLOHEXYL-) ETHYL-] PHENYL-4-METHYLBENZOATE HYDROCHLORIDE, METHOD FOR THE PRODUCTION THEREOF AND THE USE THEREOF | |
| IN2012DN03169A (ar) | ||
| TH92860A (ar) | ||
| TH146678A (th) | สารประกอบไซโคลโพรเพน |